The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2024

Filed:

Mar. 18, 2022
Applicant:

Immatics Biotechnologies Gmbh, Tuebingen, DE;

Inventors:

Toni Weinschenk, Tuebingen, DE;

Steffen Walter, Houston, TX (US);

Jens Fritsche, Tuebingen, DE;

Colette Song, Tuebingen, DE;

Harpreet Singh, Tuebingen, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/08 (2019.01); C07K 7/08 (2006.01); C12N 5/0783 (2010.01); C12N 9/64 (2006.01); A61K 38/17 (2006.01); C07K 7/06 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); A61K 38/1709 (2013.01); A61K 39/0011 (2013.01); A61K 45/06 (2013.01); C07K 7/06 (2013.01); C07K 14/7051 (2013.01); C12N 5/0638 (2013.01); C12N 9/6491 (2013.01); C12Y 304/24065 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); C12N 2502/11 (2013.01);
Abstract

A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.


Find Patent Forward Citations

Loading…